Crossmark

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer

Crossref DOI link: https://doi.org/10.1007/s10637-016-0334-y

Published Online: 2016-02-29

Published Print: 2016-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kyriakopoulos, Christos E.

Heath, Elisabeth I.

Eickhoff, Jens C.

Kolesar, Jill

Yayehyirad, Mulusew

Moll, Thomas

Wilding, George

Liu, Glenn
Funding

Funding for this research was provided by:

Adamis Pharmaceuticals Corporation, San Diego, CA

NIH/NCI (P30 CA014520)

PCCTC (PC131933)
License Information

Text and Data Mining valid from 2016-02-29

Version of Record valid from 2016-02-29
More Information

Article History

Received: 2 December 2015

Accepted: 23 February 2016

First Online: 29 February 2016

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below